Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide with or without ADE chemotherapy for chromosome 5 abnormal AML or high-risk MDS
2008-004891-28Phase 2Completed
- Sponsor
- Leeds Teaching Hospitals Trust
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Leeds Teaching Hospitals Trust. Primary endpoint: Early death rate. Started May 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2008-004891-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004891-28.